Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation develops and markets therapies for rare cardiopulmonary and related diseases, with a pulmonary arterial hypertension franchise built around treprostinil products such as Tyvaso DPI, Tyvaso Inhalation Solution, Remodulin and Orenitram. News commonly covers product sales, quarterly results, clinical data for pulmonary hypertension, idiopathic pulmonary fibrosis and interstitial lung disease, and updates on ralinepag and the TETON program.
The company also reports developments in manufactured-organ and transplant-support technologies, including EVLP, xenotransplantation, and Miromatrix Medical programs such as miroliverELAP and mirokidney. Governance updates, board composition, share repurchase activity and its status as a public benefit corporation are recurring corporate themes.
United Therapeutics (Nasdaq: UTHR) will present 11 new data presentations at ISHLT 2026 (April 22-25, Toronto), covering pulmonary hypertension, interstitial lung disease, ex vivo lung perfusion (EVLP), and xenotransplantation. Key interim analyses include ARTISAN (treprostinil effects) and PHINDER (non-invasive PH detection in ILD).
Presentations also cover machine-learning for donor lung acceptance, EVLP storage comparisons, and xenotransplantation lung and heart sizing and monitoring advances.
United Therapeutics (Nasdaq: UTHR) announced the FDA has granted RMAT designation to its investigational miroliverELAP®, an external bioengineered liver to provide temporary support for acute liver failure (ALF) patients.
The device showed positive Phase 1 signals announced in January; full study results will be published in the second half of 2026. miroliverELAP remains investigational and is not approved for any use. United Therapeutics and Miromatrix are also developing a bioengineered kidney, mirokidney®, using the same technology.
United Therapeutics (Nasdaq: UTHR) reported that the TETON-1 pivotal study of nebulized Tyvaso (treprostinil) met its primary endpoint, showing superiority vs placebo with an absolute FVC change of +130.1 mL at week 52 (H-L estimate; 95% CI 82.2–178.1; p <0.0001).
Integrated TETON-1/TETON-2 analyses showed a +111.8 mL FVC benefit (95% CI 79.7–144.0; p <0.0001), reduced risk of clinical worsening, benefits across subgroups, and a plan to seek priority review of a supplemental NDA by the end of this summer.
United Therapeutics (Nasdaq: UTHR) reported full Phase 3 TETON-2 results showing nebulized Tyvaso met the primary endpoint in idiopathic pulmonary fibrosis (IPF).
At week 52, mean absolute FVC change was −49.9 mL for Tyvaso versus −136.4 mL for placebo (between-group difference 95.6 mL; P<0.001); clinical worsening risk fell 29% (HR 0.71; P=0.02). Study enrolled 597 patients; 75.4% were on background antifibrotic therapy. No new safety signals observed. United Therapeutics plans an sNDA filing in the second half of 2026.
United Therapeutics (Nasdaq: UTHR) authorized a $2.0 billion share repurchase program and entered into $1.5 billion of Accelerated Share Repurchase (ASR) agreements with Citibank, comprising $750 million uncollared and $750 million collared ASRs.
The company will make an upfront payment of $1.5 billion on or around March 11, 2026 and receive initial share deliveries (about 70% of uncollared and 50% of collared amounts), with final settlements expected in Q2 and Q3 2026.
United Therapeutics (Nasdaq: UTHR) will present a company overview at the Leerink Global Healthcare Conference on Monday, March 9, 2026, from 1:00–1:30 p.m. EDT. Dr. Martine Rothblatt, Chairperson and CEO, will deliver the presentation.
The session will be available via live webcast on the company's investor site and an archived recording will be posted about 24 hours later and accessible for 90 days.
United Therapeutics (Nasdaq: UTHR) reported that the phase 3 ADVANCE OUTCOMES study of ralinepag met its primary endpoint, reducing risk of clinical worsening by 55% versus placebo (HR 0.45, 95% CI 0.33–0.62; p<0.0001).
Secondary benefits included a 47% increase in odds of clinical improvement (Week 28; p=0.015). United Therapeutics plans an NDA submission by H2 2026 and held a webcast March 2, 2026.
United Therapeutics (Nasdaq: UTHR) reported record full year 2025 revenue of $3.18 billion, up 11% versus 2024, and net income of $1.33 billion. Fourth-quarter revenue was $790.2 million and net income was $364.3 million. Tyvaso revenues and Tyvaso DPI volume rose materially in 2025.
The company cited continued commercial uptake, IRA Part D changes supporting utilization, higher R&D investment, a $21.7 million PP&E impairment, and litigation accruals recorded in the year.
United Therapeutics (Nasdaq: UTHR) will present a company overview at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 from 2:30–3:00 p.m. EST. Michael Benkowitz, President and COO, will deliver the presentation.
The session will be available via live webcast on the company website and an archived recording will be posted about 24 hours later and available for 90 days.
United Therapeutics (Nasdaq: UTHR) will report fourth quarter and full year 2025 financial results before the market opens on Wednesday, February 25, 2026.
A press release will be issued at approximately 6:30 a.m. ET, followed by a public webcast at 9:00 a.m. ET accessible at https://ir.unither.com/events-and-presentations. A rebroadcast will be available for one year at the same location.